NCT00337935View on ClinicalTrials.gov

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

PHASE2CompletedINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Renal Failure , ChronicAnemia

Interventions

DRUG

Epoetin Alfa

Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks

OTHER

Standard of care

All Listed Sponsors

collaborator

Ortho Biotech Clinical Affairs, L.L.C.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00337935 - A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities. | Biotech Hunter | Biotech Hunter